NEU2

Across TCGA pan-cancer cohorts, NEU2 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated NEU2 data layer compared with 16 for mass-spec protein.

The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher NEU2 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated NEU2 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

SKCM, KIRC, and MESO are the cancer types where NEU2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SKCM	DFS	Median	All	0.950	0.726	.003	14	view →
KIRC	OS	Median	All	0.263	0.810	.015	12	view →
MESO	DFS	Median	All	0.092	0.369	.003	9	view →
LUSC	OS	Median	All	0.138	0.818	.003	8	view →
CESC	OS	Median	All	0.576	0.875	.038	6	view →
SCLC	OS	Median	All	0.082	0.822	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

NEU2–SKCM (DFS)

Open the SKCM breakdown →